Asahi Kasei's venture capital strategy focuses on investing in early-stage innovative companies across diverse sectors, including advanced materials, smart homes, and healthcare solutions, to create new long-term business opportunities for the parent company. Additionally, its pharmaceutical venture arm specifically targets early-stage biotech firms developing innovative therapeutics and platforms of strategic interest.
Their most common stage is series-c (40% of deals). Average disclosed round size is $30.2M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series C
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Kins | Series A | $7M | Jul 2024 |
 Avation Medical | Series C | $22M | Feb 2024 |
 AM Batteries | Series B | $30M | Dec 2023 |
 Plant Prefab | Series B | $42M | Dec 2022 |
 Super | Series C | $50M | May 2021 |
Top Co-Investors
Wells Fargo1 shared
Gaingels1 shared
Reach Capital1 shared
Aquiline1 shared
Liberty Mutual1 shared
Moderne Ventures1 shared
Western Technology Investment1 shared
Amazon1 shared
Obvious Ventures1 shared
ShangBay Capital1 shared
Angelini Ventures1 shared
JobsOhio1 shared
Avestria1 shared
Toyota1 shared
Porsche Investments1 shared
Wilson Sonsini1 shared
Industry Ventures1 shared
Anzu Partners1 shared
TDK Ventures1 shared
Creative Ventures1 shared
Last updated: 8 March 2026